CYP2C19 Inhibitors

CYP2C19 inhibitors include, but are not limited to, cimetidine, esomeprazole, fluconazole, fluvoxamine, fluoxetine, ketoconazole, loratidine, modafinil, omeprazole, and voriconazole. See glossary page for more information.

Summary

CYP2C19 inhibitors are compounds that reduce the activity of the CYP2C19 enzyme, which can reduce drug metabolism, potentially impacting the effects of drug therapy.

CYP2C19 is a cytochrome P450 (CYP) enzyme found primarily in the liver that is involved in the metabolism of any medications that are CYP2C19 substrates.[1] CYP2C19 inhibitors can reduce the body’s metabolism of these medications.

The table below outlines some of the most common or clinically relevant CYP2C19 inhibitors.[2][1][3] Importantly, this list is not exhaustive.

CYP2C19 Inhibitors
Cimetidine
Esomeprazole
Fluconazole
Fluoxetine
Fluvoxamine
Ketoconazole
Loratidine
Modafinil
Omeprazole
Voriconazole

References

2.^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
3.^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)